Viking Therapeutics has partnered with CordenPharma, a contract development and manufacturing organization (CDMO), to manufacture its obesity drugs worth $150 million. The partnership aims to produce billions of clinical and commercial doses of the company’s GLP-1/GIP receptor agonist, a promising treatment for obesity.
Source: https://endpts.com/viking-therapeutics-taps-cordenpharma-to-manufacture-its-obesity-drugs